EP1436329A4 - Anti-pdgf antibodies and methods for producing engineered antibodies - Google Patents

Anti-pdgf antibodies and methods for producing engineered antibodies

Info

Publication number
EP1436329A4
EP1436329A4 EP02775937A EP02775937A EP1436329A4 EP 1436329 A4 EP1436329 A4 EP 1436329A4 EP 02775937 A EP02775937 A EP 02775937A EP 02775937 A EP02775937 A EP 02775937A EP 1436329 A4 EP1436329 A4 EP 1436329A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
methods
pdgf
producing engineered
engineered antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02775937A
Other languages
German (de)
French (fr)
Other versions
EP1436329A1 (en
Inventor
Katherine S Bowdish
Shana Frederickson
Anke Kretz-Rommel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of EP1436329A1 publication Critical patent/EP1436329A1/en
Publication of EP1436329A4 publication Critical patent/EP1436329A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
EP02775937A 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies Withdrawn EP1436329A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32354401P 2001-09-20 2001-09-20
US32353701P 2001-09-20 2001-09-20
US323544P 2001-09-20
US323537P 2001-09-20
US37999402P 2002-05-13 2002-05-13
US379994P 2002-05-13
PCT/US2002/030086 WO2003025019A1 (en) 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies

Publications (2)

Publication Number Publication Date
EP1436329A1 EP1436329A1 (en) 2004-07-14
EP1436329A4 true EP1436329A4 (en) 2005-04-27

Family

ID=27406282

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02775937A Withdrawn EP1436329A4 (en) 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies

Country Status (4)

Country Link
EP (1) EP1436329A4 (en)
JP (1) JP2005512962A (en)
CA (1) CA2460587A1 (en)
WO (1) WO2003025019A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
JP4723810B2 (en) * 2001-12-03 2011-07-13 アレクシオン ファーマシューティカルズ, インコーポレイテッド Hybrid antibody
JP2006503547A (en) * 2002-02-11 2006-02-02 アレクシオン ファーマシューティカルズ, インコーポレイテッド Immunotherapy for biological weapons defense
US7619070B2 (en) * 2003-04-23 2009-11-17 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
DK1660057T3 (en) * 2003-08-27 2012-08-20 Ophthotech Corp Combination therapy for the treatment of neovascular eye disorders
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2009129538A2 (en) * 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2014519813A (en) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ,エルエルシー Use of EMT gene signatures in cancer drug discovery, diagnosis, and treatment
JO3787B1 (en) 2012-03-15 2021-01-31 Janssen Biotech Inc Human anti-cd27 antibodies, methods, and uses
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
BR112014032316A2 (en) * 2012-06-28 2017-06-27 Molecular Partners Ag engineered ankyrin repeat proteins that bind to platelet-derived growth factor
AU2013323553B2 (en) 2012-09-27 2018-07-12 Allergan, Inc. Biodegradable drug delivery systems for the sustained release of proteins
EP2968574A1 (en) 2013-03-14 2016-01-20 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process
US20150017163A1 (en) 2013-07-12 2015-01-15 Ophthotech Corporation Methods for Treating or Preventing Ophthalmological Conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024059A1 (en) * 1997-11-07 1999-05-20 Massachusetts Institute Of Technology Pdgf-mediated microvascular communication and methods of use thereof
WO1999029888A1 (en) * 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6180370B1 (en) * 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180370B1 (en) * 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
WO1999024059A1 (en) * 1997-11-07 1999-05-20 Massachusetts Institute Of Technology Pdgf-mediated microvascular communication and methods of use thereof
WO1999029888A1 (en) * 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BROECKER M ET AL: "Excessive activation of tyrosine kinases leads to inhibition of proliferation in a thyroid carcinoma cell line.", LIFE SCIENCES. 1998, vol. 63, no. 26, 1998, pages 2373 - 2386, XP002307362, ISSN: 0024-3205 *
CHUNTHARAPAI ANAN ET AL: "Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE", CYTOKINE, vol. 15, no. 5, 7 September 2001 (2001-09-07), pages 250 - 260, XP002307361, ISSN: 1043-4666 *
See also references of WO03025019A1 *
SHIMIZU S ET AL: "In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, no. 12, December 2000 (2000-12-01), pages 1285 - 951, XP002960893, ISSN: 0910-5050 *
WU H ET AL: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 151 - 162, XP004461859, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
WO2003025019A9 (en) 2004-05-06
EP1436329A1 (en) 2004-07-14
CA2460587A1 (en) 2003-03-27
WO2003025019A8 (en) 2004-04-01
WO2003025019A1 (en) 2003-03-27
JP2005512962A (en) 2005-05-12

Similar Documents

Publication Publication Date Title
EP1436329A4 (en) Anti-pdgf antibodies and methods for producing engineered antibodies
EP1432444A4 (en) Anti-a-beta antibodies
HK1074206A1 (en) Anti-trail-r antibodies
IL212419A0 (en) Methods of administering anti-tnf antibodies
AU2002346641A8 (en) Apertured non-woven composites and method for making
EP1635872A4 (en) Antibodies and fusion proteins that include engineered constant regions
IL225633A0 (en) Anti-alpha-v-beta - 6 antibodies and uses thereof
IL157142A0 (en) Modified antibodies and methods of use
EP1514928A4 (en) Method for producing antibodies
EP1551447A4 (en) Anti-addl antibodies and uses thereof
AU4002001A (en) High potency recombinant antibodies and method for producing them
HUP0402333A3 (en) Modified anti-tnf alpha antibody
GB0128287D0 (en) Novel method and compounds
AU2003259861A8 (en) Antibody pair screening methods
AU2002365649A8 (en) Anti-dota antibody
AU2002359495A8 (en) Anti-tnf antibodies, compositions, methods and uses
EP1367611A4 (en) Inductor part, and method of producing the same
GB2387599B (en) Methods for producing antibodies
AU2002367943A8 (en) Improved reagents and methods for producing parvoviruses
EP1621616A4 (en) Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
IL166063A0 (en) Antibodies and uses thereof
EP1380646A4 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
TWI318239B (en) Methods for producing novel medaka and novel medaka
GB0221940D0 (en) Antibody and screening method
EP1336848A4 (en) Highly efficient method of screening antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050308

17Q First examination report despatched

Effective date: 20050808

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071219